Fig. 3: Tracking of DNA origami in vivo integrity using PLASTIQ.
From: Resolving DNA origami structural integrity and pharmacokinetics in vivo
a, Experimental workflow for i.v. or i.p. injection of the origami into mice, collection of blood samples from the same subject animal at different time points, PLASTIQ protocol processing, pooled PCR amplification and gel assay or sequencing analysis. b,c, Gel assays including PAGE (b) and intensity (c) analyses of products from the pooled PCR for the amplification of ligated LSPs from the blood of mice injected with origami via i.v. administration. The different lanes correspond to blood samples collected at different time points. The dots represent the two biological replicates. Ctrl, control corresponding to a blood sample collected 5 min post-injection without the ligation step. d,e, Gel assays including PAGE (d) and intensity (e) analyses of the products from the PCR amplification of ligated LSPs from blood of mice injected with origami via i.p. administration. The different lanes correspond to blood samples collected at different time points. The dots represent the two biological replicates. Ctrl, control corresponding to a blood sample collected 5 min post-injection without the ligation step. f, Fluorescence imaging of blood samples collected at different time points after injecting mice with Alexa 750 dye or dye-labelled nanostructures. g, Alexa 750 fluorescence-based blood pharmacokinetic curves. h, Fluorescence imaging of live mice at 1- and 2-h post-injection. I, dye; II, dye-labelled origami; III, dye-labelled PEGylated origami.
